Journal
CLINICAL IMMUNOLOGY
Volume 118, Issue 1, Pages 77-82Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2005.09.005
Keywords
multiple sclerosis; disease-modifying therapy; interferon beta; neurotrophins; brain-derived neurotrophic factor; nerve growth factor; glial cell line-derived neurotrophic factor; neurotrophin 3; neurotrophin 4/5; neuroprotection
Categories
Ask authors/readers for more resources
Although interferon (IFN) beta is a widely used disease-modifying therapy ill multiple sclerosis (MS), the mechanisms responsible for its effects are not fully understood. Some studies demonstrated that IFNbeta induces nerve growth factor (NGF) secretion by astrocytes and by brain endothelial cells. In this study, we determined the production of various neurotrophins (brain-derived neurotrophic factor, BDNF; NGF; glial cell line-derived neurotrophic factor, neurotrophin 3; neurotrophin 4) by peripheral blood mononuclear cells (PBMCs) in relapsing-remitting (RR) and secondary progressive (SP) MS patients during IFNbeta treatment. There were no main variations in neurotrophin production either among all MS patients globally considered or in the group of SPMS subjects. Instead, in the group of RRMS patients who did not present clinical exacerbation of disease up to the end of the study, we found a significant increase in BDNF production as from 6 months after starting therapy. (c) 2005 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available